CA2896957A1 - Characterizing a glatiramer acetate related drug product - Google Patents

Characterizing a glatiramer acetate related drug product Download PDF

Info

Publication number
CA2896957A1
CA2896957A1 CA2896957A CA2896957A CA2896957A1 CA 2896957 A1 CA2896957 A1 CA 2896957A1 CA 2896957 A CA2896957 A CA 2896957A CA 2896957 A CA2896957 A CA 2896957A CA 2896957 A1 CA2896957 A1 CA 2896957A1
Authority
CA
Canada
Prior art keywords
cells
expression
level
glatiramer acetate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2896957A
Other languages
English (en)
French (fr)
Inventor
Rivka SCHWARTZ
Shlomo BAKSHI
Kevin Daniel FOWLER
Fadi George TOWFIC
Jason Michael Funt
Benjamin James ZESKIND
Maksym ARTOMOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2896957(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2896957A1 publication Critical patent/CA2896957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2896957A 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product Abandoned CA2896957A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361749228P 2013-01-04 2013-01-04
US61/749,228 2013-01-04
US201361819481P 2013-05-03 2013-05-03
US61/819,481 2013-05-03
PCT/US2014/010103 WO2014107533A2 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Publications (1)

Publication Number Publication Date
CA2896957A1 true CA2896957A1 (en) 2014-07-10

Family

ID=51061235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896957A Abandoned CA2896957A1 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Country Status (17)

Country Link
US (1) US20140193827A1 (enExample)
EP (1) EP2941274A4 (enExample)
JP (1) JP2016504039A (enExample)
KR (1) KR20150111945A (enExample)
CN (1) CN105228651A (enExample)
AU (1) AU2014204043A1 (enExample)
BR (1) BR112015016169A2 (enExample)
CA (1) CA2896957A1 (enExample)
CL (1) CL2015001915A1 (enExample)
EA (1) EA201591251A1 (enExample)
HK (1) HK1216299A1 (enExample)
IL (2) IL239692A0 (enExample)
MX (1) MX2015008754A (enExample)
PE (1) PE20151980A1 (enExample)
SG (1) SG11201505210RA (enExample)
WO (1) WO2014107533A2 (enExample)
ZA (1) ZA201505367B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
JP7276664B2 (ja) * 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
WO2004028339A2 (en) * 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP2009509142A (ja) * 2005-09-19 2009-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法
US8753833B2 (en) * 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
EP2365825A1 (en) * 2008-11-18 2011-09-21 Crossbeta Biosciences B.V. Cross-beta structures as carriers in vaccines
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy

Also Published As

Publication number Publication date
CL2015001915A1 (es) 2016-11-11
BR112015016169A2 (pt) 2017-07-11
EA201591251A1 (ru) 2016-05-31
KR20150111945A (ko) 2015-10-06
IL252547A0 (en) 2017-07-31
IL239692A0 (en) 2015-08-31
SG11201505210RA (en) 2015-07-30
EP2941274A4 (en) 2016-11-16
PE20151980A1 (es) 2016-01-15
ZA201505367B (en) 2016-11-30
MX2015008754A (es) 2016-04-11
WO2014107533A2 (en) 2014-07-10
EP2941274A2 (en) 2015-11-11
CN105228651A (zh) 2016-01-06
US20140193827A1 (en) 2014-07-10
HK1216299A1 (zh) 2016-11-04
WO2014107533A3 (en) 2015-01-29
AU2014204043A1 (en) 2015-08-13
JP2016504039A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
CA2896957A1 (en) Characterizing a glatiramer acetate related drug product
AU2014232794A1 (en) Dendritic cell response gene expression, compositions of matters and methods of use thereof
EP3695408A1 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US20190284531A1 (en) Detection of t cell exhaustion or lack of t cell costimulation and uses thereof
US20250270640A1 (en) Antigen reactive t-cell receptors
Paley et al. The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells
EP4448799A2 (en) Molecular signatures for cell typing and monitoring immune health
WO2017136709A2 (en) Molecular assays for regulating immunosuppression, averting immune-mediated rejection and increasing graft survival
JP2012527895A (ja) 被移植者における免疫寛容に伴うｂ細胞の特性
US20220033464A1 (en) Methods and compositons for modulations of immune response
US20170003277A1 (en) Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
Amancherla et al. Single-cell RNA-sequencing identifies unique cell-specific gene expression profiles in high-grade cardiac allograft vasculopathy
US12461101B2 (en) Blood-based signatures for diagnosis and sub-typing of inflammatory bowel disease subsets
US20240150453A1 (en) Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
US20200017921A1 (en) Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
US20240067970A1 (en) Methods to Quantify Rate of Clonal Expansion and Methods for Treating Clonal Hematopoiesis and Hematologic Malignancies
JP2024541909A (ja) 乳がんの腫瘍微小環境タイプ
TW201610169A (zh) 利用哺乳動物及人類細胞進行之格拉雷姆（ｇｌａｔｉｒａｍｅｒ）乙酸鹽相關藥物產品之生物特徵化
US20260112450A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockage therapies and combinations thereof
JP2024541067A (ja) がん生存及びｃａｒ ｔ細胞毒性を予測するための方法及び組成物
Sun et al. Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia
Zavacky Investigating the heterogeneity of tumour-associated macrophages in renal cell carcinoma milieu
US20240344132A1 (en) Method of Treating Liver Cancer, Predicting Response to Treatment, and Predicting Adverse Effects During the Treatment Thereof
Popovich Computational Drug Repositioning and 3D Skin-Like Tissues Identify Anti-Fibrotic Targets for Systemic Sclerosis (SSc)
Munasinghe et al. A Myeloid Lineage Signifying Anti-Tumor Necrosis Factor Resistance in Crohn’s Disease.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190102

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: T-6-6-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240828